Iceland· IS-EU/1/22/1695/001
Zynlonta
A loncastuximab tesirine product containing loncastuximabum tesirinum inn, registered in Iceland by Swedish Orphan Biovitrum AB (publ). The same ATC class is registered in 11 of our 19 countries.
Checked against Icelandic Medicines Agency (Iceland) on
Informational only — not a medical device.
Where it is registered
Loncastuximab tesirine is registered in 11 of 19 countries.
Countries holding a registration under ATC L01FX22 (loncastuximab tesirine), each read from that country’s own register.
- This record: Iceland, from Icelandic Medicines Agency (Iceland)
- 7 of them publish a price we can compare per daily dose
Loncastuximab tesirine · ATC L01FX22
11 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- United Kingdom
- United Statesprice
The record
At a glance
Icelandic Medicines Agency (Iceland)- Active substance
- loncastuximabum tesirinum INN
- Manufacturer
- Swedish Orphan Biovitrum AB (publ)
- Country
- Iceland (IS)
- ATC code
- L01FX22
- ATC class
- Loncastuximab tesirine
- Defined daily dose
- 0.25 mg, P
- Reimbursed
- Not published by this register
- Source register
- Icelandic Medicines Agency (Iceland)
- Last checked
- September 29, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Loncastuximab tesirine in 10 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumZynlonta 10 mgSwedish Orphan Biovitrum (Publ)
- CzechiaZYNLONTASwedish Orphan Biovitrum AB (publ), Stockholm
- SpainZYNLONTA 10 MG POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONSwedish Orphan Biovitrum Ab (Publ)
- FinlandZynlontaSwedish Orphan Biovitrum AB (publ)
- United KingdomZynlonta 10mg powder for concentrate for solution for infusion vialsSwedish Orphan Biovitrum Ltd
- IrelandZynlonta 10 mg powder for concentrate for solution for infusionSwedish Orphan Biovitrum AB
- PolandZynlontaSwedish Orphan Biovitrum AB (publ)
- SwedenZynlonta 10 mg Pulver till koncentrat till infusionsvätska, lösningSwedish Orphan Biovitrum AB (publ)
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Liechtenstein · Zynlonta
- Norway · Zynlonta
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Icelandic Medicines Agency (Iceland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ea14b08e-a326-4df1-8f86-dcacc230ad15 GET /v1/drugs/ea14b08e-a326-4df1-8f86-dcacc230ad15?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Stofn fyrir innrennslisþykkni, lausn",
"source": "lyfjastofnun",
"atc_raw": "L01FX22",
"marketed": false,
"strength": "10 mg",
"ma_number": "EU/1/22/1695/001",
"substance": "loncastuximabum tesirinum INN",
"other_info": null,
"legal_status": "(R) Lyfseðilsskylt\r\n(H) Sjúkrahúsmerkt",
"ma_issued_serial": "44915"
}See everything about loncastuximab tesirine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.